论文部分内容阅读
目的:探讨维拉帕米对左室舒张期心力衰竭患者的疗效。方法:84例舒张期心力衰竭患者,随机分成A组,42例,给予血管紧张素转换酶抑制剂(ACEI)+利尿剂标准治疗;B组,42例,在标准治疗基础上加用维拉帕米,随访30周。治疗前后测量六分钟步行试验的距离和检测血浆脑钠肽(BNP)的浓度进行对比,评价维拉帕米对单纯左室舒张期心力衰竭(DHF)的疗效。结果:维拉帕米治疗30周后与A组相比,B组6min步行距离明显提高(P<0.05);血浆BNP浓度明显降低(P<0.05)。结论:维拉帕米联用ACEI+利尿剂能进一步改善DHF患者的左室舒张功能,疗效确切。
Objective: To investigate the efficacy of verapamil in patients with left ventricular diastolic heart failure. Methods: Eighty-four patients with diastolic heart failure were randomly divided into group A (n = 42) and standard angiotensin converting enzyme inhibitor (ACEI) plus diuretic. Group B (n = 42) Pamy, followed up for 30 weeks. The six-minute walk test before and after treatment was compared with the concentration of plasma brain natriuretic peptide (BNP) to evaluate the effect of verapamil on left ventricular diastolic heart failure (DHF). Results: After 30 weeks of verapamil treatment, the walking distance at 6min in group B was significantly higher than that in group A (P <0.05). Plasma BNP concentration was significantly lower (P <0.05). Conclusion: Verapamil combined with ACEI + diuretic can further improve left ventricular diastolic function in patients with DHF, the curative effect is correct.